{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010755","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.084070+00:00","generated_at":"2026-06-17T09:18:19.286079+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptevo reports 2022 net income of $8.0M on $37.2M gain; cash down to $22.6M","bullets":["Net income of $8.0M ($1.57 diluted EPS) vs net loss of $28.5M in 2021; includes $37.2M gain on extinguishment of royalty liability.","Royalty revenue fell to $3.1M from $12.3M due to amendment of royalty purchase agreement with HCR.","Cash and equivalents $22.6M at Dec 31, 2022, down from $45.0M a year earlier.","APVO436 Phase 1b data showed activity in AML; Phase 2 planned for 2H23. ALG.APV-527 Phase 1 first patient dosed Feb 2023.","Preclinical candidate APV0711 (anti-PD-L1/anti-CD40) filed provisional patent; preclinical studies initiated Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010755","json":"https://secwatch.observer/filing/0000950170-23-010755.json","markdown":"https://secwatch.observer/filing/0000950170-23-010755.md","text":"https://secwatch.observer/filing/0000950170-23-010755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023010755/0000950170-23-010755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023010755/apvo-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:18:19.286079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0441f86f9b58db5b217c1c7636f5b62a8679e755","claim":"Aptevo Therapeutics Inc. reported year ended December 31, 2022 results: revenue $22.6 million.","evidence_excerpt":"preliminary results from the study later this year.” 3 2022 Summary Financial Results Cash Position: Aptevo had cash and cash equivalents as of December 31, 2022 totaling $22.6 million. Royalty Revenue: Royalty revenue for the period covered by this report reflects revenue recorded only in the first quarter of 2022 due to our Amendment to Royalty Purchase","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023010755/0000950170-23-010755-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Revenue","value":"$22.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}